

Original article

Rapid decline of kidney function in diabetic kidney disease is associated with high soluble Klotho levels[☆]

Flaviu Bob^a, Adalbert Schiller^a, Romulus Timar^{b,*}, Daniel Lighezan^c, Oana Schiller^d, Bogdan Timar^e, Cristiana Georgeta Bujor^f, Mircea Munteanu^b, Florica Gadalean^a, Adelina Mihaescu^a, Iulia Grosu^a, Andreea Hategan^b, Lazar Chisavu^a, Agneta-Maria Pusztai^g, Adrian Covic^h

^a Nephrology Department, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania

^b Diabetes and Metabolic Diseases Department, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania

^c Internal Medicine 1 Department, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania

^d BBraun Avitum Dialysis Center, Timisoara, Romania

^e Medical Informatics and Biostatistics Department, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania

^f Biochemistry Department, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania

^g Anatomy Department, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania

^h Nephrology Department, Dialysis and Renal Transplant Center, “Dr. C.I. Parhon” University Hospital, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania

ARTICLE INFO

Article history:

Received 14 April 2018

Accepted 25 August 2018

Keywords:

s-Klotho

KIM-1

Tubular injury

Diabetic kidney disease

ABSTRACT

Background: Klotho is found in two forms: a transmembrane form and a soluble form (s-Klotho). In order to be excreted, s-Klotho, that is too large to be filtered, will probably reach the proximal convoluted tubule by a transcytosis process. The aim of our study was to show the relationship between the levels of s-Klotho and tubular injury in patients with diabetic kidney disease (DKD), using as tubular injury marker the kidney injury molecule-1 (KIM-1).

Methods: Our study included 63 DKD patients (stages 1–5, mean eGFR 65.15 ± 32.45 ml/min) with a mean age 58.13 ± 12 years. In all patients we determined serum levels of: KIM-1 and s-Klotho using ELISA, urinary albumin/creatinine ratio (UACR) and reduction in the estimated glomerular filtration rate (eGFR) per year.

Results: We found a strong statistically significant correlation of s-Klotho with the rate of reduction of eGFR/year ($r=0.714$, $p=0.0004$) and with the tubular injury marker KIM-1 ($r=0.758$, $p=0.005$) and strong correlations of UACR with the rate of reduction of eGFR/year ($r=0.53$, $p<0.01$), KIM-1 ($r=0.49$, $p<0.05$) and s-Klotho ($r=0.52$, $p<0.01$).

Conclusion: Despite previous published data, that shows a decrease of s-Klotho in chronic kidney disease, in our study the rapid annual decline of kidney function but not the level

[☆] Authors Flaviu Bob and Adalbert Schiller had an equal contribution to this study.

* Corresponding author.

E-mail address: rtimar@yahoo.com (R. Timar).

<http://dx.doi.org/10.1016/j.nefro.2019.04.002>

of eGFR was associated with increased s-Klotho. A possible explanation could be a more severe proximal tubule injury that could lead to a reduction of tubular excretion of s-Klotho as suggested by the correlation of s-Klotho levels with the serum levels of KIM-1.

© 2018 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

El rápido deterioro de la función renal en la nefropatía diabética se asocia con niveles elevados de Klotho soluble

R E S U M E N

Palabras clave:

s-Klotho
KIM-1
Lesión tubular
Enfermedad renal diabética

Antecedentes: Klotho se encuentra en el organismo en dos formas: una forma transmembrana y una forma soluble (s-Klotho). Para excretarse s-Klotho, que es demasiado grande para ser filtrado, llegará en el túbulo contorneado proximal por un proceso de transcitosis. El objetivo del presente estudio es indicar la relación entre el nivel de s-Klotho y lesión tubular en los pacientes con la enfermedad renal diabética (DKD), utilizando como marcador de lesión tubular renal kidney injury molecule-1 (KIM-1).

Métodos: Nuestro estudio incluye 63 pacientes con DKD (etapas 1-5, eGFR medio 65,15 +/- 32,45 ml/min) con una edad media de 58,13 +/- 12 años. En todos los pacientes hemos determinado el nivel sérico de: KIM-1 y s-Klotho utilizando el método ELISA, coeficiente albúmina/creatinina urinaria (UACR) y la reducción de la tasa de filtración glomerular estimada (eGFR) al año.

Resultados: Hemos encontrado una correlación fuerte significativa desde el punto de vista estadístico de s-Klotho con una tasa de reducción de eGFR/año ($r = 0,714$, $p = 0,0004$) y con el marcador de lesión tubular KIM-1 ($r = 0,758$, $p = 0,005$) y una fuerte correlación de UACR con una tasa de reducción de eGFR/año ($r = 0,53$, $p < 0,01$), KIM-1 ($r = 0,49$, $p < 0,05$) y s-Klotho ($r = 0,52$, $p < 0,01$).

Conclusiones: A pesar de los datos publicados anteriormente en la literatura, que demuestran una reducción de s-Klotho en la enfermedad crónica de riñones, en nuestro estudio, la disminución rápida anual de la función renal y no el nivel de eGFR se correlaciona con el crecimiento de s-Klotho. Una posible explicación podría ser una lesión tubular proximal más grave que podría llevar a la reducción de la excreción tubular de s-Klotho, sugerida por la correlación de s-Klotho con el nivel sérico de KIM-1.

© 2018 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The identification of Klotho gene was important because it encodes a single-pass transmembrane co-receptor protein, expressed mainly (but not only) in the kidney, involved in the antiaging process. The Klotho protein is composed of a large extracellular and a small intracellular domain.¹

The Klotho gene knock-out mice expresses a phenotype of premature aging: shortened life span, growth retardation, hypogonadism, skin and muscle atrophies, vascular calcification, cognition impairment, motor neuron degeneration and others.² These actions are associated with phosphate balance disorders since transmembrane klotho acts as a co-receptor for FGF23, a hormone involved in phosphate reabsorption at the proximal tubule level and inhibition of the synthesis of active vitamin D.³

The extracellular domain of Klotho, after proteolytic cleavage, is released in the extracellular space as soluble Klotho (s-Klotho), identifiable in blood, urine, cerebrospinal fluid.

s-Klotho exerts a phosphaturic effect, independent of FGF23 by inactivating the Na-Pi-2a transporter at the proximal tubule level. Beside the phosphaturic effect, soluble klotho has also other endocrine effects, such as inhibition of insulin-like growth factor (IGF)-1 receptors, inhibition of TGF beta mediated fibrogenesis, cytoprotection among others.⁴

The kidney is the main contributor to s-klotho production, and is also the major organ where s-klotho is retrieved from the circulation probably through tubular transcytosis.⁵ The question is how does chronic kidney disease (CKD) influence the level and functions of s-Klotho?

The aim of our study was to assess the level of s-Klotho in patients with diabetic kidney disease (DKD), the leading cause of end-stage renal disease,⁶ in relation with the rate of renal function decline. It is known that part of the patients with DKD are nonalbuminuric, suggesting that partly the decline of eGFR in diabetic patients is due to tubulo-interstitial injury⁷ and therefore we have studied the relationship of s-klotho with markers of tubular damage and with markers of interstitial fibrosis.

Methods

Study population

The study was performed in the University Nephrology Clinic of the “Pius Brnzeu” Emergency County Hospital Timisoara, Romania. After signing an informed consent, we included 63 patients (30 female, 33 male) with a mean age of 58.13 ± 12 years. All of the patients have been previously diagnosed with DKD (stages G1–G5) in the Diabetes and Metabolic Diseases Clinic, according to the criteria of the American Diabetes Association as the presence of an eGFR <60 ml/min/1.73 m² or the presence of albuminuria >30 mg/g creatinine.⁸ All patients were already treated with either ACE inhibitors or AII receptor blockers. All the patients were at their first referral to a nephrologist, thus none of them was previously diagnosed with CKD mineral bone disorder and none treated with vitamin D or phosphate binders. Patients undergoing renal replacement therapies have not been included. Demographic information, medical history (including duration of diabetes mellitus and history of eGFR in the past 12 months) were retrieved from the GP's and hospital data base in all cases.

Biochemical analysis

In every fasting patient after signing the informed consent spot urine and blood specimens were collected. We obtained the following parameters: serum creatinine (mg/dl), serum calcium (mg/dl), serum phosphorus (mg/dl), iPTH (pg/ml) and spot urinary albumin creatinine ratio (UACR – mg/g creatinine).

Serum creatinine has been performed using the Dimension Chem I Calibrator, traceable to the National Institute of Standards and Technology (NIST) Standard Reference Material (SRM) 914.

Estimated glomerular filtration rate (eGFR) was obtained in every patient using the CKD Epidemiology Collaboration equation (CKD-Epi), and the CKD stage was defined according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.⁹ We calculated the reduction of eGFR as the difference between current eGFR and previous eGFR (12 months earlier, obtained from the patient's files) divided through previous eGFR multiplied with 100, and we obtained the percentage of eGFR decrease.

ELISA technique

Blood samples collected from the patients on the day of admission were assessed using ELISA technique in order to obtain serum levels of: soluble klotho, kidney injury molecule-1 (KIM-1), connective tissue growth factor (CTGF), fibroblast growth factor 23 (FGF23). We used the following commercially available antigen laboratory kits:

- Anti-Klotho antibody. The kit from AbbeXa™ is based on sandwich enzyme-linked immune-sorbent assay technology. An horseradish peroxidase (HRP) conjugated anti-Klotho antibody is used as detection antibody.

Tetramethyl-benzidin (TMB) substrate was used to visualize HRP enzymatic reaction.

- Boster's human KIM1 ELISA Kit, based on standard sandwich enzyme-linked immune-sorbent assay technology, that is a monoclonal antibody from mouse specific for KIM-1.
- OmniKine™ Human CTGF ELISA Kit, contains the components necessary for quantitative determination of natural or recombinant Human CTGF concentrations. This particular immunoassay utilizes the quantitative technique of a “Sandwich” Enzyme-Linked Immunosorbent Assay (ELISA) where the target protein (antigen) is bound in a “sandwich” format by the primary capture antibodies coated to each well-bottom and the secondary detection antibodies added subsequently by the investigator.
- Human FGF23 ELISA Kit (Aviscera Bioscience Inc.) contains the necessary components required for the quantitative measurement of recombinant and/or natural human FGF23 from serum and plasma in a sandwich ELISA format.

Statistical analysis

Data were collected and analysed using the SPSS v.17 software suite (SPSS Inc., Chicago, IL, USA) and are presented as mean \pm standard deviations for continuous variables with Gaussian distribution, median (interquartile range) for continuous variables without Gaussian distribution, or percentages for categorical variables. To assess the significance of the differences between groups, the Student t-test (means, Gaussian populations), Mann-Whitney U test (medians, non-Gaussian populations) and Chi-square (proportions) were used. Continuous variable distributions were tested for normality using Shapiro-Wilk test, and for equality of variances using Levene's test. The strength of the association between continuous variables was evaluated using Spearman's correlation coefficient. Since the primary hypothesis was to evaluate a possible relationship between s-Klotho and the amplitude of renal function decrease (an outcome which may be influenced by several other factors), besides the bivariate correlation between s-Klotho and Δ eGFR a multivariate regression model was built to evaluate the association between the two components, adjusted for confounding factors.

A *p* value of <0.05 was considered as the threshold for statistical significance.

Results

The studied group baseline characteristics are presented in Table 1.

In our cohort we found a mean reduction of eGFR over the previous 12 months of $19.23 \pm 15.01\%$ corresponding to 11.6 ± 8.24 ml/min/1.73 m²/year.

We divided the studied subjects into those with eGFR >60 ml/min/1.73 m² – 34 patients (this group included patients with DKD stage 1 and 2) and 29 patients with eGFR <60 ml/min/1.73 m² (this group included patients with DKD stages 3–5 ND).

The main correlations found comparing the studied variables are presented in Table 2.

Table 1 – The baseline characteristics of the included patients.

	Mean value ± SD
Age (years)	58.13 ± 12
eGFR (ml/min/1.73 m ²)	65.15 ± 32.45
Serum calcium (mg/dl)	9.2 ± 0.61
Serum phosphate (mg/dl)	3.8 ± 0.9
Urinary albumin/creatinine ration (mg/g)	381 ± 986
s-Klotho (pg/ml)	326.36 ± 246.78
FGF23 (pg/ml)	147.37 ± 124.7
iPTH (pg/ml)	62.85 ± 65.35
KIM-1 (pg/ml)	212.67 ± 256.3
CTGF (pg/ml)	66.45 ± 5.3

As expected s-Klotho correlated negatively with the age of the patients ($r = -0.31, p = 0.014$). The s-Klotho level did not correlate with eGFR, however, on average it was higher (but not significantly) in patients with eGFR below 60 ml/min/1.73 m². We found a strong correlation of s-Klotho with the rate of reduction of eGFR/year ($r = 0.714, p = 0.0004$) and with the tubular injury marker KIM-1 ($r = 0.758, p = 0.005$) (Figs. 1 and 2).

KIM-1 levels showed a similar pattern: no correlation with eGFR but a strong correlation with the rate of reduction of eGFR/year ($r = 0.554, p = 0.0004$) (Fig. 3).

We found strong correlations of urinary albumin/creatinine ratio with the rate of reduction of eGFR/year ($r = 0.53, p < 0.01$), KIM-1 ($r = 0.49, p < 0.05$) and s-Klotho ($r = 0.52, p < 0.01$).

To evaluate the main hypothesis of the study (the association between s-Klotho and the amplitude of renal function decline), considering that the renal function decline may be influenced by several other factors, to adjust the relationship for confounding factors we built a multivariate regression model, having as outcome the eGFR rate of decline and predictors: s-Klotho, CTGF, patient's age, HbA1c and BMI (Table 3).




Fig. 1 – Correlation between s-Klotho (Klotho) and the rate of reduction of eGFR/year.

The results of the multivariate regression model are pointing that the values of s-Klotho are significantly associated with the decline of the renal function both in the univariate model as well as after adjusting for possible confounding factors. According to the resulted model, in our scenario, after confounding adjustments we observed that for one increase with a standard deviation in the s-Klotho value we may expect an augmentation of the renal function decline (as evaluated using ΔeGFR) with 0.623 standard deviations.

This model revealed also that a significant predictor of the renal function decline in this cohort of patients was the BMI value (an increased BMI being associated in the multivariate model with an increased rate of decline in the renal function).

Table 2 – Correlations found between the studied variables (S-Klotho, KIM-1, rate of reduction of eGFR/year – Delta GFR, iPTH, FGF23, CTGF).

			s-Klotho	KIM-1	Delta GFR	iPTH	FGF23	CTGF
Spearman's rho	s-Klotho	Correlation coefficient	1.000	.758**	.714**	-.557**	-.269*	.106
		Sig. (2-tailed)	.000	.000	.000	.000	.033	.408
	KIM-1	Correlation coefficient	.758**	1.000	.554**	-.440**	-.296*	.098
		Sig. (2-tailed)	.000	.000	.000	.000	.018	.445
	Delta GFR	Correlation coefficient	.714**	.554**	1.000	-.433**	-.299*	.224
		Sig. (2-tailed)	.000	.000	.000	.000	.017	.078
	iPTH	Correlation coefficient	-.557**	-.440**	-.433**	1.000	.176	-.101
		Sig. (2-tailed)	.000	.000	.000	.000	.168	.430
	FGF23	Correlation coefficient	-.269*	-.296*	-.299*	.176	1.000	-.240
		Sig. (2-tailed)	.033	.018	.017	.168	.058	1.000
	CTGF	Correlation coefficient	.106	.098	.224	-.101	-.240	1.000
		Sig. (2-tailed)	.408	.445	.078	.430	.058	
		N	63	63	63	63	63	63

** Correlation is significant at the 0.01 level (2-tailed).

* Correlation is significant at the 0.05 level (2-tailed).




Fig. 2 – Correlation between s-Klotho (Klotho) and serum Kidney injury molecule-1 (KIM-1).




Fig. 3 – Correlation between KIM-1 and the rate of reduction of eGFR/year.

Discussion

In the recent years a high number of research papers are addressing Klotho genetics, functions and possible use for early diagnosis in CKD, prognostic assessment in CKD and associated cardiovascular disease (CVD). The s-Klotho level was proposed as a biomarker for early stages of CKD.¹⁰ Higher

soluble klotho levels proved to be independently associated with a lower risk for decline of the kidney function,¹¹ while reduced levels were associated with higher cardiovascular and all-cause mortality.¹² However contradictory results have also been published at least concerning mortality in CKD patients.^{13,14} s-Klotho was also proposed as a possible therapeutic measure.¹⁵ In mice with CKD restoring the Klotho level induced negative phosphate balance through inhibition of renal phosphate transporters and prevented vascular calcification by inhibiting phosphate uptake.¹⁶ A recent experimental study showed that recombinant Klotho protein is effective in preventing or retarding acute kidney injury progression to CKD in mice.¹⁷

The highest expression of membrane Klotho was evidenced at the kidney level and with the progression of CKD its level is decreasing.¹⁸ Animal studies have shown that the kidney is the main source of s-Klotho.¹⁹ Thus, because presumably the majority of s-Klotho is derived from renal membrane Klotho, renal function decline should be associated with a decrease of s-Klotho. Studies performed in patients with CKD stages 1–5 HD, show a decrease of s-Klotho compared to normal subjects, the decrease being more important with the progression of CKD.^{20,21} Even in the absence of a deterioration of renal function after nephrectomy in living renal donors, a decrease of s-Klotho has been observed.²²

Despite the data presented before, in our study patients with eGFR below 60 ml/min, had on average higher s-Klotho levels as compared to those with higher eGFR (without reaching statistical significance). Instead we found a strong statistically correlation between the level of s-Klotho and the rate of decrease of eGFR/year ($r=0.714$, $p=0.0004$), thus patients that showed a faster progression of CKD had higher levels of s-Klotho.

The differences reported in the level of s-Klotho by different authors, are probably explained by an assay-related variance,⁴ however there is data, supporting our observations, showing an increase of s-Klotho in CKD^{23–25} or in acute kidney injury (AKI).²⁶ The question is why s-Klotho levels are not always decreasing with the progression of kidney disease, following the pattern of membrane klotho?

It is known that in subjects with CKD the expression of renal Klotho is severely impaired, reaching levels as far as 5% of those encountered in subjects without renal impairment,² but serum levels of s-Klotho in patients with CKD, are only modestly reduced compared to values reported in healthy adults.²⁷

Thus the circulating level of Klotho does not probably reflect the level of tissue Klotho, especially in patients with

Table 3 – Multivariate regression analysis of the rate of reduction of eGFR/year.

Dependent variable: Δ eGFR	Unstandardized coefficients		Standardized coefficients Beta	t	p-Value
	B	Std. error			
(Constant)	-14.475	32.002		-0.452	0.665
s-Klotho	0.023	0.009	0.623	2.680	0.032
CTGF	-0.017	0.023	-0.196	-0.736	0.486
Age	0.023	0.257	0.026	0.090	0.931
BMI	0.631	0.270	0.625	2.223	0.042
HbA1c	-0.108	1.222	-0.026	-0.088	0.932

CKD.⁸ This could be due to the extrarenal origin of s-Klotho (parathyroids,²⁸ choroid processes, vascular wall).

The discrepancies between the higher level of circulating s-Klotho and decreased renal function could also be attributed to a decreased excretion. The route of excretion of s-klotho is unknown. An indirect proof of the presence of s-Klotho in urine is the independent phosphaturic effect exerted at tubular level. Soluble Klotho acts from the urinary luminal side as an autocrine or paracrine enzyme to regulate transporters and ion channels, the phosphaturic effect being obtained by modifying the Na⁺-phosphate cotransporter NaPi-2a. This effect is independent of FGF23.²⁹ The presence of s-Klotho in the urine but not in the Bowman's space was evidenced in an animal model after injecting Klotho i.v. supporting the fact that s-Klotho is too large (130 kDa) to be filtered through the glomerular barrier.³⁰ Most probably to reach the lumen of the proximal tubules, s-Klotho undergoes a transcytosis process, at the level of the proximal tubules.⁵

In case of a nonfunctioning kidney it is unclear what happens to the production and clearance of Klotho. Extra-renal Klotho production might be low or undetectable in normal conditions, or even in acute loss of renal function, but could possibly be stimulated in chronic Klotho deficiency. Another interesting finding, supporting the role of renal tubules in the clearance of s-Klotho in the failing kidney, was evidenced in peritoneal dialysis patients. Serum s-Klotho levels turned out to be negatively correlated with the urine output rather than with the remaining kidney function expressed by eGFR.³¹

Considering the hypothesis of the tubular transcytosis of s-Klotho, and the negative correlation of the serum level of s-Klotho with urine output, we raise the question of the relationship between s-Klotho and tubular injury, also because tubular basement membrane thickening and tubular atrophy belong to the classical interstitial pathological changes in DKD.⁷

Kidney injury molecule-1 (KIM-1) is a transmembrane tubular protein expressed in response to tubular injury, being a sensitive marker of acute kidney injury. The increase of urinary KIM-1, due to its link to tubular atrophy could also be used to predict progression of CKD,³² but the question is if plasma levels of KIM-1 are useful as well. In a study performed by Alter et al. proximal tubular injury due to onset diabetes in rats leads to elevated plasma KIM-1 levels.³³ Plasma KIM-1 is considered the first blood biomarker that specifically reflects injury to the proximal tubule of the kidney.³⁴ In patients with diabetes, increased plasma KIM-1 levels are associated to an increased risk of renal function decline.³⁵

We observed in our study that plasma KIM-1 is higher in DKD patients with eGFR <60 ml/min (239.6 vs. 173.3), however without statistical significance ($p=0.5$). But we found a strong positive correlation of plasma KIM-1 with the rate of reduction of eGFR/year, showing thus a correlation between chronic tubular injury and renal function decline. We have also found that increased plasma KIM-1 levels are associated with increased s-Klotho levels, suggesting the hypothesis that more severe proximal tubular injury is associated to increased levels of s-Klotho. So it is possible that the more rapid progression of DKD in our patients is related to more severe proximal

tubule injury than other mechanisms (at least in our cohort of patients).

Another interesting relationship that we have found is the direct correlation of urinary albumin/creatinine ratio with KIM-1 levels and s-klotho. This could emphasize the above hypothesis, that lesion of the proximal tubular cells is associated also to an increase in albuminuria, besides the increase of s-Klotho. The relationship between tubular injury and albuminuria has been explained by a hypothetical "retrieval pathway" of filtered albumin, that returns albumin through a transcytosis process to the peritubular blood supply.³⁶ Injury at the tubular level could thus lead to an increase in albuminuria, like we have observed in our cohort, and it could also explain the correlation observed between albuminuria and s-Klotho.

One of the pleiotropic effects of s-klotho is the anti-fibrosis effect.³⁷ Because this effect is linked to the potential benefits of restoring klotho levels, we have tried to assess if there is a relationship between s-klotho levels and a biomarker of fibrogenesis. CTGF is suggested to be a contributor to the tubulointerstitial fibrosis that accompanies proteinuria in CKD.³⁸ However, in our patients we could not find any statistically significant correlation between s-Klotho and CTGF, and therefore this issue needs more extensive study in the future. Another important aspect is the relationship between s-Klotho and age, because it is known that Klotho was discovered as an aging gene. In our patients we found a decrease of s-Klotho in older patients. Other authors that measured s-Klotho showed higher levels in children,³⁹ but a weaker⁴⁰ or no relationship with age in adults.⁴¹

A particularity of the studied patient group is the rather high rate of renal function decline, higher compared to the decline reported in the literature for DKD.⁴² According to the KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease we could define our results as a rapid decline of the renal function (>5 ml min/year).⁴³ One explanation could be that our included patients were all recent referrals to the nephrologist, without previous intervention strategies of delaying renal disease progression.

An important limitation of the study is related to the technical difficulty of the s-Klotho measurement, resulting from the lack of standardization between the different commercially available kits, and also by the fact that a cross-reactivity with other analytes cannot be excluded.⁴⁴ To the limitations of our study we would count the relatively small number of patients and the fact that data is not analyzed prospectively; the small sample size analyzed may lead to type II statistical errors by not having enough statistical power to reject the null hypothesis. Even if the sample size is small and the lack of statistical power may lead to some inferential impairments, we do not consider this a major drawback considering the exploratory and innovative character of the study; the results of associations, even some of them not being demonstrated as statistically significant may lead to novel, revolutionary approaches regarding the role of s-Klotho in chronic kidney disease. For a better assessment of the relationship with CKD-MBD markers the level of phosphaturia and also collecting data regarding the dietary phosphate intake would have been of help.

Conclusions

Despite previous published data, that shows a decrease of s-Klotho in chronic kidney disease, in our study the rapid annual decline of kidney function but not the level of eGFR was associated with increased s-Klotho levels. A possible explanation could be a more severe proximal tubule injury that could lead to a reduction of tubular excretion of s-Klotho as suggested by the correlation of s-Klotho levels with the serum levels of KIM-1. Future human studies are needed in order to reveal the relationship between tubular injury and s-Klotho in chronic kidney disease.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval number 183E-94) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors have declared that no conflict of interest exists.

Acknowledgments

The study was supported by a research grant (PIII-C1-PCFI-2015/2016) of the University of Medicine and Pharmacy “Victor Babes” Timisoara, Romania.

REFERENCES

- [1]. Kuro-o M. Klotho and the aging process. *Korean J Intern Med.* 2011;26:113–22.
- [2]. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, et al. Severely reduced production of Klotho in human chronic renal failure kidney. *Biochem Biophys Res Commun.* 2001;280:1015–20.
- [3]. Gattineni J, Baum M. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. *Pediatr Nephrol.* 2010;25:591–601.
- [4]. Golembiewska E, Stępniewska J, Kabat-Koperska J, Kędzierska K, Domański M, Ciechanowski K. The role of klotho protein in chronic kidney disease: studies in animals and humans. *Curr Protein Pept Sci.* 2016;17:821–6.
- [5]. Hu MC, Shi M, Zhang J, Addo T, Cho HJ, Barker SL, et al. Renal production, uptake, and handling of circulating alpha klotho. *J Am Soc Nephrol.* 2016;27:79–90.
- [6]. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. *Am J Kidney Dis.* 2014;64:510–33.
- [7]. Chen C, Wang C, Hu C, Han Y, Zhao L, Zhu X, et al. Normoalbuminuric diabetic kidney disease. *Front Med.* 2017;11:310–8.
- [8]. American Diabetes Association. Standards of medical care in diabetes – 2015 abridged for primary care providers. *Clin Diabetes.* 2015;33:97–111.
- [9]. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150:604–12.
- [10]. Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, et al. Serum levels of soluble secreted α -Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. *Clin Exp Nephrol.* 2012;16:722–9.
- [11]. Drew DA, Katz R, Kritchevsky S, Ix J, Shlipak M, Gutiérrez OM, et al. Association between soluble klotho and change in kidney function: the health aging and body composition study. *J Am Soc Nephrol.* 2017;28:1859–66.
- [12]. Otani-Takei N, Masuda T, Akimoto T, Honma S, Watanabe Y, Shiizaki K, et al. Association between serum soluble klotho levels and mortality in chronic hemodialysis patients. *Int J Endocrinol.* 2015, <http://dx.doi.org/10.1155/2015/406269>.
- [13]. Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, et al. Associations of FGF23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2–4. *Clin J Am Soc Nephrol.* 2014;9:1049–58.
- [14]. Nowak A, Friedrich B, Artunc F, Serra AL, Breidhardt T, Twerenbold R, et al. Prognostic value and link to atrial fibrillation of soluble Klotho and FGF23 in hemodialysis patients. *PLOS ONE.* 2014;9:e100688, <http://dx.doi.org/10.1371/journal.pone.0100688> [eCollection 2014].
- [15]. Neyra JA, Hu MC. Potential application of klotho in human chronic kidney disease. *Bone.* 2017;20, <http://dx.doi.org/10.1016/j.bone.2017.01.017>. S8756-3282(17)30017-0.
- [16]. Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. *J Am Soc Nephrol.* 2011;1:124–36.
- [17]. Hu MC, Shi M, Gillings N, Flores B, Takahashi M, Kuro-o M, et al. Recombinant α -Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. *Kidney Int.* 2011;7:1104–14.
- [18]. Hu MC, Kuro-o M, Moe OW. Klotho and chronic kidney disease. *Contrib Nephrol.* 2013;180:47–63.
- [19]. Lindberg K, Amin R, Moe OW, Hu MC, Erben RG, Östman Wernerson A, et al. The kidney is the principal organ mediating klotho effects. *J Am Soc Nephrol.* 2014;25:2169–75.
- [20]. Yokoyama K, Imura A, Ohkido I, Maruyama Y, Yamazaki Y, Hasegawa H, et al. Serum soluble α -Klotho in hemodialysis patients. *Clin Nephrol.* 2012;77:347–51.
- [21]. Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, et al. Secreted Klotho and FGF23 in chronic kidney disease stage 1 to 5: a sequence suggested from a cross-sectional study. *Nephrol Dial Transplant.* 2013;28:352–9.
- [22]. Akimoto T, Kimura T, Watanabe Y, Ishikawa N, Iwazu Y, Saito O, et al. The impact of nephrectomy and renal transplantation on serum levels of soluble Klotho protein. *Transplant Proc.* 2013;45:134–6.
- [23]. Sugiura H, Tsuchiya K, Nitta K. Circulating levels of soluble α -Klotho in patients with chronic kidney disease. *Clin Exp Nephrol.* 2011;15:795–6.
- [24]. Devaraj S, Syed B, Chien A, Jialal I. Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. *Am J Clin Pathol.* 2012;137:479–85.
- [25]. Kacso IM, Bondor CI, Kacso G. Soluble serum klotho in diabetic nephropathy: relationship to VEGF-A. *Clin Biochem.* 2012;45(16–17):1415–20.

- [26]. Seibert E, Radler D, Ulrich C, Hanika S, Fiedler R, Girndt M. Serum klotho levels in acute kidney injury 2017. *Clin Nephrol*. 2017;87:173–9.
- [27]. Komaba H, Koizumi M, Tanaka H, Takahashi H, Sawada K, Kakuta T, et al. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. *Nephrol Dial Transplant*. 2012;27:1967–9.
- [28]. Takahashi H, Komaba H, Takahashi Y, Sawada K, Tatsumi R, Kanai G, et al. Impact of parathyroidectomy on serum FGF23 and soluble klotho in hemodialysis patients with severe secondary hyperparathyroidism. *J Clin Endocrinol Metabol*. 2014;99:E652–8.
- [29]. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. *FASEB J*. 2010;24:3438–50.
- [30]. Hu MC, Shi M, Zhang J, Quiñones H, Kuro-o M, Moe OW. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. *Kidney Int*. 2010;78:1240–51.
- [31]. Golembiewska E, Safranow K, Kabat-Koperska J, Myślak M, Ciechanowski K. Serum soluble Klotho protein level is associated with residual diuresis in incident peritoneal dialysis patients. *Acta Biochim Pol*. 2013;60:191–4.
- [32]. Lobato GR, Lobato MR, Thomé FS, Veronese FV. Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetyl- β -D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes. *Braz J Med Biol Res*. 2017;30:e6106.
- [33]. Alter ML, Kretschmer A, von Websky K, Tsuprykov O, Reichetzeder C, Simon A, et al. Early urinary and plasma biomarkers for experimental diabetic nephropathy. *Clin Lab*. 2012;58:659–71.
- [34]. Sabbiseti VS, Waikar SS, Antoine DJ, Smiles A, Wang C, Ravisankar A, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. *J Am Soc Nephrol*. 2014;25:2177–86.
- [35]. Nowak N, Skupien J, Niewczas MA, Yamanouchi M, Major M, Croall S, et al. Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. *Kidney Int*. 2016;89:459–67.
- [36]. Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM. Disease dependent mechanisms of albuminuria. *Am J Physiol Renal Physiol*. 2008;295:F1589–600.
- [37]. Huang CL, Moe OW. Klotho: a novel regulator of calcium and phosphorus homeostasis. *Pflugers Arch*. 2011;462:185–93.
- [38]. Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, et al. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. *Diabetes Care*. 2003;26:2632–6.
- [39]. Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y, et al. Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. *Biochem Biophys Res Commun*. 2010;398:513–8.
- [40]. Seiler S, Wen M, Roth HJ, Fehrenz M, Flügge F, Herath E, et al. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. *Kidney Int*. 2013;83:121–8.
- [41]. Inci A, Sari F, Olmaz R, Coban M, Dolu S, Sarikaya M, et al. Soluble Klotho levels in diabetic nephropathy: relationship with arterial stiffness. *Eur Rev Med Pharmacol Sci*. 2016;20:3230–7.
- [42]. Sheen YJ, Sheu WH. Risks of rapid decline renal function in patients with type 2 diabetes. *World J Diabetes*. 2014 Dec 15;5:835–46.
- [43]. Kidney Disease: Improving Global Outcomes (KDIGO), CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*. 2013;3:1–150.
- [44]. Heijboer AC, Blankenstein MA, Hoenderop J, de Borst MH, Vervloet MG, NIGRAM consortium. Laboratory aspects of circulating α -Klotho. *Nephrol Dial Transplant*. 2013;28:2283–7.